IDEAYA Biosciences Reports End?of?Phase 1 Meeting with FDA for IDE196 Confirms Acceptability of Single-Arm Trial Design for Potential Phase 2 Registration-Enabling Study in Metastatic Uveal Melanoma

0
4

IDEAYA Biosciences Reports End?of?Phase 1 Meeting with FDA for IDE196 Confirms Acceptability of Single-Arm Trial Design for Potential Phase 2 Registration-Enabling Study in Metastatic Uveal Melanoma

LEAVE A REPLY

Please enter your comment!
Please enter your name here